Jan 30, 2020
Organizational and Personnel Changes
TOKYO, January 30, 2020 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced today the following organizational changes, effective April 1, 2020, and personnel changes, effective March 30 and April 1, 2020.
[Details of Organizational Changes]
Effective April 1, 2020
1. Abolition of Secretarial Dept. and reorganization of secretarial function
To enable efficient and flexible executive support, Secretarial Dept. will be integrated into General Affairs Dept., where Secretarial Office will be newly established. In addition, functions related to executive compensation will be transferred from Secretarial Dept. to Human Resources Management Dept. in order to integrate operation of the executive compensation system (directors and executive officers) and the personnel systems.
2. Abolition of PV & Safety Science Dept., and reorganization into two new departments (Drug Safety Div.)
To establish a safety strategy function capable of handling various new businesses, PV & Safety Science Dept. will be abolished and replaced by Safety Strategy Dept. and Pharmacovigilance Dept., which are newly established with the following aims.
- Safety Strategy Dept.: to strengthen the safety science function
- Pharmacovigilance Dept.: to improve efficiency and quality of the individual case safety report/the adverse drug reaction management
3. Renaming of Business Assessment Dept. (Project & Lifecycle Management Unit)
Business Assessment Dept. will be renamed Business Insights & Strategy Dept. in order to describe the department’s roles and mission more accurately and to ensure consistency with its counterpart at Roche while the Company will streamline and strengthen functions to capture business insights and create business strategies for in-house projects in early stages of development.
[Details of Personnel Changes]
Effective March 30, 2020
Directors
Name | New Responsibilities | Current Responsibilities |
---|---|---|
Tatsuro Kosaka | Representative Director, Chairman Chief Executive Officer (CEO) Supervisory responsibility for Corporate Planning, Business Development, External Affairs, and Foundation Medicine |
Representative Director, President CEO Supervisory responsibility for External Affairs, Pharmaceutical Technology, and Marketing & Sales |
Osamu Okuda | Representative Director, President Chief Operating Officer (COO) Supervisory responsibility for Project & Lifecycle Management, Regulatory & Quality Management, Clinical Development, Pharmaceutical Technology, Drug Safety, Medical Affairs, and Marketing & Sales Co-Head of Project & Lifecycle Management Unit |
Executive Vice President Supervisory responsibility for Project & Lifecycle Management (Marketing), Foundation Medicine, Corporate Planning, and Business Development Co-Head of Project & Lifecycle Management Unit |
Mariko Momoi | Director | - |
- Osamu Nagayama is scheduled to retire from Representative Director, Chairman as of March 30, 2020 and to be appointed as Honorary Chairman.
- Yasuo Ikeda is scheduled to retire from Director as of March 30, 2020.
- The appointment of Osamu Okuda and Mariko Momoi as Directors is subject to approval at the 109th Annual General Meeting of Shareholders, which is scheduled to be convened on March 30, 2020.
Executive officer
Name | New Responsibilities | Current Responsibilities |
---|---|---|
Yasushi Ito | Executive Vice President Co-Head of Project & Lifecycle Management Unit |
Executive Vice President Supervisory responsibility for Project & Lifecycle Management (R&D), Regulatory & Quality Management, Clinical Development, Drug Safety, and Medical Affairs Co-Head of Project & Lifecycle Management Unit |
Audit & Supervisory Board Member
Name | New Responsibilities | Current Responsibilities |
---|---|---|
Kenichi Masuda | Audit & Supervisory Board Member | - |
- The appointment of Kenichi Masuda as Audit & Supervisory Board Member is subject to approval at the 109th Annual General Meeting of Shareholders, which is scheduled to be convened on March 30, 2020.
- Hisashi Hara is scheduled to retire from Audit & Supervisory Board Member as of March 30, 2020.
Effective April 1, 2020
Director
Name | New Responsibilities | Current Responsibilities |
---|---|---|
Osamu Okuda | Representative Director, President COO Supervisory responsibility for Project & Lifecycle Management, Regulatory & Quality Management, Clinical Development, Pharmaceutical Technology, Drug Safety, Medical Affairs, and Marketing & Sales |
Representative Director, President COO Supervisory responsibility for Project & Lifecycle Management, Regulatory & Quality Management, Clinical Development, Pharmaceutical Technology, Drug Safety, Medical Affairs, and Marketing & Sales Co-Head of Project & Lifecycle Management Unit |
Executive officers
Name | New Responsibilities | Current Responsibilities |
---|---|---|
Shinya Unno | Deputy President Supervisory responsibility for Human Resources Management, Human Capital Development, Legal, Intellectual Property, and General Affairs In charge of General Affairs Dept. |
Executive Vice President Supervisory responsibility for Human Resources Management, Human Capital Development, Legal, Intellectual Property, General Affairs, and Secretarial General Manager of Human Resources Supervisory Div. In charge of General Affairs Dept. and Secretarial Dept. |
Toshiaki Itagaki | Executive Vice President Chief Financial Officer (CFO) Supervisory responsibility for Finance & Accounting, Corporate Communication, Purchasing, Digital Strategy, and IT Solution General Manager of Finance Supervisory Div. |
Executive Vice President CFO Supervisory responsibility for Finance & Accounting, Corporate Communication, Purchasing, Digital Strategy, and IT Solution General Manager of Finance Supervisory Div. and General Manager of Finance & Accounting Dept. |
Tetsuya Yamaguchi | Senior Vice President General Manager of Corporate Planning Dept. and Head of Foundation Medicine Unit |
Vice President General Manager of Business Development Dept. |
Mark Noguchi | Senior Vice President General Manager of Business Development Dept. |
- |
Minoru Watanabe | Vice President Head of Project & Lifecycle Management Unit |
Vice President General Manager of Corporate Planning Dept. and Head of Foundation Medicine Unit |
Shinji Hidaka | Vice President General Manager of Marketing & Sales Div. |
Vice President General Manager of Medical Affairs Div. |
Yoshiyuki Yano | Vice President General Manager of Human Resources Supervisory Div. and General Manager of Human Resources Management Dept. |
Vice President General Manager of Human Resources Management Dept. |
Junichi Nezu | Vice President General Manager of Research Div. |
Associate Vice President General Manager of Research Div. |
Tsukasa Kusano | Vice President General Manager of Clinical Development Div. |
Associate Vice President Deputy General Manager of Marketing & Sales Div. |
Kaori Ouchi | Vice President General Manager of Medical Affairs Div. and Department Manager of Medical Science Dept., Medical Affairs Div. |
Department Manager of Medical Science Dept., Medical Affairs Div. |
Masatoshi Takada | Vice President Head of Kansai Regional Management Office, Marketing & Sales Div. |
Associate Vice President Head of Kansai Regional Management Office, Marketing & Sales Div. |
- Yasushi Ito is scheduled to retire from Executive Vice President as of March 31, 2020.
- Toshihiko Komori, Hisanori Takanashi, Tsunanori Sato, and Kouichi Nishikawa are scheduled to retire from Vice Presidents as of March 31, 2020. Hisanori Takanashi is scheduled to be appointed as an Advisor (full-time).
Please see the PDF file about other personnel changes.
Contact:
- For Media
- Chugai Pharmaceutical Co., Ltd.
- Media Relations Group, Corporate Communications Dept.,
- Tomoko Shimizu
- Tel: +81-3-3273-0881
- E-mail: pr@chugai-pharm.co.jp
- For Investors
- Chugai Pharmaceutical Co., Ltd.
- Investor Relations Group, Corporate Communications Dept.,
- Toshiya Sasai
- Tel: +81-3-3273-0554
- E-mail: ir@chugai-pharm.co.jp